

MEN'99



S E V E N T H I N T E R N A T I O N A L W O R K S H O P O N M U L T I P L E E N D O C R I N E N E O P L A S I A

**Congress Center Park Hotel ai Cappuccini
Gubbio - Italy**

June 30 - July 2, 1999

Final programme / Abstract book

Tuesday June 29, 1999

14.00 p.m.

**OPENING OF SECRETARIAT AND DISTRIBUTION OF BADGES AND
CONFERENCE BAGS TO ALL PRE-REGISTERED PARTICIPANTS.**

Scientific Programme

Wednesday June 30, 1999

08.00 a.m.

OPENING

08.30 a.m.

PLENARY LECTURE I

Chairmen: Magnus Nordenskjöld, Sw and Charles E. Jackson, USA

STRUCTURAL AND ULTRASTRUCTURAL FEATURES OF MEN TUMORS

Cesare Bordi, I

p. 9

09.00 a.m.

PLENARY SESSION I

MEN I: GENERAL FEATURES

Clinical features and pathophysiology of MEN 1

Stephen J. Marx, USA

p. 13

Menin function: a role in AP1-mediated gene regulation

Sunita Agarwal, USA

p. 19

MEN1 gene mutations in MEN 1 and related syndromes

Catharina Larsson, Sw

p. 25

10.15 a.m.

Coffee Break

10.30 a.m.

Menin protein: structural and functional aspects

Siradanahalli C. Guru, USA

p. 31

MEN1: phenotype/genotype correlations in MEN1

Alain Calender, F

p. 35

MEN 1: genetic counselling

Rajesh V. Thakker, UK

p. 41

12.00 noon-13.15 p.m.

POSTER SESSION I

from p. 161 to p. 230

13.15 p.m. - 15.00 p.m.

Lunch



15.00 p.m. - 17.15 p.m.

PLENARY SESSION II

MEN 1: CLINICAL MANAGEMENT

Chairmen: Giovanni Faglia, I and Eitan Friedman, IL

MEN 1 hyperparathyroidism: diagnosis and treatment

Samuel A. Wells Jr., USA

p. 45

MEN1 Zollinger-Ellison syndrome: diagnosis and treatment

Norman W. Thompson, USA

p. 51

MEN1 insulinoma: diagnosis and treatment

Guido Tamburrano, I

p. 55

MEN1 pituitary tumors: diagnosis and treatment

Anna Spada, I

p. 63

MEN1 carcinoids: diagnosis and treatment

Robert T. Jensen, USA

p. 67

19.00 p.m.

Light Dinner

20.30 p.m. - 22.30 p.m.

INTERNATIONAL COLLABORATIVE STUDIES from p. 299 top. 313
Chairmen: Alberto Falchetti, I and Friedhelm Raue, D

Thursday July 1, 1999

With the support of  **NOVARTIS**

08.30 a.m.

PLENARY LECTURE II

Chairmen: Giancarlo Vecchio, I and Gilbert Lenoir, F

MEDICAL THERAPY OF MEN 1 AND MEN 2

Britt Skogseid, Sw

p. 73

09.00 a.m.

PLENARY SESSION III

MEN 2: GENERAL FEATURES

Clinical management of MEN 2: is there an additional clinical phenotype?

Robert F. Gagel, USA

p. 77

Ret gene mutations in MEN 2 and related syndromes

Wolfgang Höppner, D

p. 79

Mechanisms of Ret-mediated cell transformation

Massimo Santoro, I

p. 85

10.15 a.m.

Coffee Break

10.30 a.m.

Genotype-phenotype correlations in MEN2; their significance for clinical management

Cornelis J.M. Lips, NL

p. 91

MEN 2: genetic counselling

Bruce A.J. Ponder, UK

p. 97

11.30 a.m. - 13.15 p.m.

POSTER SESSION II

from p.231 to p. 298

13.15 p.m. - 15.00 p.m.

Lunch



15.00 p.m. - 17.15 p.m.

PLENARY SESSION IV

MEN 2: CLINICAL MANAGEMENT

Chairmen: Bruce A.J. Ponder, UK and Aldo Pinchera, I

Hereditary medullary thyroid carcinoma: clinical management

Bruce G. Robinson, AUS

p. 101

Sporadic medullary thyroid carcinoma: diagnosis and treatment

Friedhelm Raue, D

p. 107

FMTc only: clinical management

Alfonso Libroia, I

p. 113

Pheochromocytoma in MEN 2: diagnosis and treatment

Bernard Conte-Devolx, F

p. 119

Sporadic pheochromocytoma: diagnosis and treatment

Massimo Mannelli, I

p. 125

20.00 p.m.

Social Dinner and Poster Awards



Friday July 2, 1999

08.30 a.m.

PLENARY LECTURE III

Chairmen: Mario Serio, I and Stephen J. Marx, USA

LOCALIZATION STUDIES OF MEN TUMORS

Steven W. Lamberts, NL

p. 131

09.00 a.m.

PLENARY SESSION V

NON MEN INHERITED ENDOCRINE TUMOR SYNDROMES

The complex of spotty pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney Complex)

Aidan J. Carney, USA

p. 133

McCune Albright syndrome: a form of multiple endocrine neoplasia caused by somatic mutation of G_s - α

Allen M. Spiegel, USA

p. 141

The role of PTEN in Cowden syndrome and multiple sporadic cancers

Charis Eng, USA

p. 147

10.15 a.m.

Coffee Break

10.30 a.m.

Von Hippel-Lindau disease

Hartmut P.H. Neumann, D

p. 153

Tuberous Sclerosis Complex

John P. Osborne, UK

p. 157

11.30 a.m.

RELEASE OF THE CONSENSUS CONFERENCE

13.30 p.m.

Lunch



End of the meeting